Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (14): 2656-2660.doi: 10.3969/j.issn.1673-8225.2012.14.039

Previous Articles    

Umbilical cord mesenchymal stem cell transplantation and rehabilitation treatment for cerebral hemorrhage sequela: 1 year follow-up 

Yuan Jin-guo1, Feng Bin1, Cao Cang-zhu1, Han Shu-sheng1, Sun Yin-chen1, Liu Jian-ling2   

  1. 1Department of Neurosurgery, 2Department of Central Experiment, the 251st Hospital of Chinese PLA, Zhangjiakou 075000, Hebei Province, China
  • Received:2011-04-01 Revised:2011-06-15 Online:2012-04-01 Published:2012-04-01
  • About author:Yuan Jin-guo, Associate chief physician, Department of Neurosurgery, the 251st Hospital of Chinese PLA, Zhangjiakou 075000, Hebei Province, China Yuanshuo160@sina.com

PDF

787

Abstract:

BACKGROUND: Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into neural cells, which have been confirmed in in vivo and in vitro experiments. There have been few clinical reports describing umbilical cord mesenchymal stem cells for treatment of cerebral hemorrhage.
OBJECTIVE: To investigate the therapeutic effects of human umbilical cord mesenchymal stem cell transplantation combined with rehabilitation treatment for cerebral hemorrhage sequela.
METHODS: Forty-five patients with cerebral hemorrhage were assigned to two groups according to admission data: treatment group (n=22) and control group (n=23). After 10-18 days of routine treatment, each patient had sequela to different extents. The treatment group received human umbilical cord mesenchymal stem cell transplantation and rehabilitation treatment and the control group only received rehabilitation treatment.
RESULTS AND CONCLUSION: All cases had been followed up for 12 months. Compared with before treatment, Fugl-Meyer scores and modified Barthel index were significantly higher at 1, 3, 6, 12 months after treatment in each group (P < 0.05). After treatment, Fugl-Meyer scores and modified Barthel index in the experimental group were significantly higher than in the control group (P < 0.05), and body movement function and daily life activities improved obviously. After 3 months of treatment, body movement function in the treatment group was more obvious, and the involvement of rehabilitation treatment could help to compensate the shortage of simple human umbilical cord mesenchymal stem cell transplantation. Cranial MRI and related biochemistry examinations have confirmed the efficiency and safety of human umbilical cord mesenchymal stem cell transplantation combined with rehabilitation treatment. This suggests that transplantation of human umbilical cord mesenchymal stem cells cultured in vitro for treatment of cerebral hemorrhage sequela has no special adverse reactions and it can acquire better effects in recovery of body movement function after combination with rehabilitation treatment.

CLC Number: